Since ClearPlasma helps to stabilize clots and subsequently to reduces blood loss we estimate that ClearPlasma will impact the following topics: A. Significantly reduces the cost of treating massive bleeding. – Most complicated massively bleeding patients have been previously treated with anticoagulants. Thus, to stop the bleeding, there is a need to reverse the effects of the anticoagulant. By efficiently removing fibrinolytic proteins such as plasminogen, ClearPlasma increases the coagulation parameters and efficiency. Patients transfused with ClearPlasma demonstrated an increased ability to form stable hemostatic clots. Moreover, the use of ClearPlasma minimized the need for expensive therapies, s that may be required after standard plasma transfusions. B. Effective treatment - clinical data shows that ClearPlasma can reduce the number of regular platelets units required during excessive bleeding by improving the clinical outcome, cost, and the number of transfusion bags used, subsequently reducing the hospitalization time. C. Safety and selectivity - ClearPlasma significantly reduces the concentration of the target protein by >90%, without altering other coagulation parameters, such as fibrinogen concentration or Partial Thromboplastin Time (PTT), or causing adverse events. Current therapies are cost-inefficient in reducing massive bleeding, risky for the patients, and leading to re-bleeding episodes (33% of patients with GI bleeding). As a consequence, additional corrective interventions are required increasing the economic burden on healthcare systems. In our clinical study, we demonstrated that no adverse events occurred using Clear Plasma compared to realgar plasma transfusion.
